To enhance service speed and avoid tariff delays, we've opened a US warehouse. All US orders ship directly from our US facility.
| Cas No.: | 176957-55-4 |
| Synonyms: | CCT-007093, CCT 007093, CCT007093 |
| SMILES: | O=C1/C(CC/C1=CC2=CC=CS2)=C/C3=CC=CS3 |
| Formula: | C15H12Os2 |
| M.Wt: | 272.39 |
| Purity: | >98% |
| Sotrage: | 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO |
| Description: | CCT 007093 is an effective PPM1D inhibitor that selectively reduces viability of human tumour cell lines.As expected of a specific inhibitor, the toxicity of CCT007093 to PPM1D overexpressing cell lines after inhibitor treatment is P38 dependent [1]. Knockdown of WIP1 or treatment with the WIP1 inhibitor CCT007093 results in increased phosphorylation of known WIP1 targets, reduced HDM2 expression, and reduced growth specifically in WIP1 wild-type and high-expressing medulloblastoma cells [2]. CCT007093 treatment appeared to promote apoptosis in breast cancer cells and skin transformed keratinocytes that ectopically expressed Wip1, demonstrating that the effect of CCT007093 differs based on the level of Wip1 expression [3] |
| Target: | PPM1D |
| References: | [1]. Rayter S, et al. A chemical inhibitor of PPM1D that selectively kills cells overexpressing PPM1D. Oncogene. 2008 Feb 14;27(8):1036-44. [2]. Buss MC, et al. HDM2 promotes WIP1-mediated medulloblastoma growth. Neuro Oncol. 2012 Apr;14(4):440-58. [3]. Lee JS, et al. Off-target response of a Wip1 chemical inhibitor in skin keratinocytes. J Dermatol Sci. 2014 Feb;73(2):125-34. |
MSDS
COA
| LOT NO. | DOWNLOAD |
|
|
|
| 2018-0101 |
|
| 2018-0101 |
|